Sign in
Not yet recruitingNo phase

Bowel rinsing with water for bowel trouble after rectal cancer surgery

Tests transanal irrigation for bowel problems after rectal cancer surgery.

Key facts

Who runs it
Seoul National University Hospital
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Transanal Irrigation for Low Anterior Resection Syndrome
Status
Not yet recruiting
People taking part
94 people, planned
Started
1 Feb 2025
Expected to end
31 Dec 2029
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Transanal Irrigation (TAI)
Record updated
28 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with major bowel problems (low anterior resection syndrome) after surgery for rectal cancer. It compares loperamide alone with loperamide plus rinsing the bowel with water through the anus.

Age
19 years and older
Sex
All sexes
Disease stage
Low or ultra-low anterior resection for rectal cancer (within 15cm (5.9 in) from the anal verge), at least 24 months after surgery, with no stoma (bag on the belly). Major LARS score.
Earlier treatment
Must have had low or ultra-low anterior resection surgery. Cannot join after radiation therapy for the cancer after surgery.

Main reasons for not taking part

  • Colorectal cancer that has come back or has spread
  • Needing a permanent colostomy
  • Inflammatory bowel disease (IBD), or constipation or diarrhea not controlled by medicine
  • Leaking of stool before the surgery
  • Other illnesses not controlled by treatment, or allergy to the study drug

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adults aged 19 years and above
  • Patients who have undergone low or ultra-low anterior resection surgery for rectal cancer (within 15cm from the anal verge)
  • Patients at least 24 months post-surgery without stoma
  • Patients evaluated with a major LARS score
  • Patients who comprehend and have the ability to participate in this clinical trial

Who cannot take part

  • Patients with concomitant metastatic colorectal cancer
  • Patients with symptoms of constipation or diarrhea not controlled by medication
  • Patients allergic to the investigational drug
  • Patients with recurrent colorectal cancer
  • Patients who have undergone postoperative cancer radiation therapy
  • Patients with underlying conditions not controlled by internal medical treatment
  • Patients with inflammatory bowel disease (IBD)
  • Patients requiring permanent colostomy
  • Patients with preoperative symptoms of fecal incontinence
  • Patients deemed unsuitable for clinical trial participation by the principal investigator and study personnel

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The preservation surgery of the anal sphincter muscle has become the standard procedure in the treatment of rectal cancer and, thanks to advancements in surgical techniques, can now be performed for tumors located closer to the anus. This method allows patients to avoid a permanent artificial anus, maintaining continuity of the intestines and enabling bowel movements through the anus, making it a highly preferred procedure. Furthermore, advancements in various tumor treatments have led to improved long-term survival rates.

Read full original descriptionShow less

Preservation surgery of the anal sphincter muscle is commonly used in the treatment of rectal cancer, resulting in approximately 90% of patients experiencing changes in bowel habits after surgery. These changes include characteristic diarrhea, urgent bowel movements, frequent bowel movements, and fecal incontinence, collectively known as Anterior Resection Syndrome (ARS). Particularly in the case of low rectal cancer, it often manifests as Low Anterior Resection Syndrome (LARS). These symptoms are most severe immediately after surgery, generally persisting in a significant degree for 1-2 years, with some improvement over time. However, for many patients, LARS remains a lifelong challenge, significantly impacting their quality of life. Nighttime symptoms of LARS, in particular, have a profound effect on sleep quality, potentially leading to a decline in overall quality of life.

Currently, there is no definitive method to completely cure LARS, and the available approaches focus on empirical treatments or short-term symptom control using medications such as loperamide.

Loperamide directly affects the neuromuscular system of the intestine, reducing its motility. This prolongs the time food stays in the intestine, allowing sufficient absorption of moisture and electrolytes, consequently reducing symptoms of diarrhea. Loperamide is available in two forms: loperamide oxide and loperamide hydrochloride. While loperamide oxide products like Arestal® were prescribed by doctors until August 2017, the approval was revoked, leaving loperamide hydrochloride as the only form used domestically. It comes in a single product containing 2 mg of loperamide hydrochloride and a combination product with 0.25 mg of loperamide hydrochloride, a sterilizing agent in the intestine (e.g., acrylonitrile, berberine), and an antispasmodic.

Transanal irrigation (TAI) is a method where patients self-administer water into the rectum through an enema, physically cleansing the anus and rectum. This technique is often used for patients with chronic constipation or fecal incontinence. TAI has proven beneficial, particularly in improving symptoms for patients experiencing bowel dysfunction following sphincter-preserving surgery, especially for those who underwent low anterior resection.

However, there is currently no research on the utility and safety of TAI for LARS patients, specifically addressing whether it can improve the nighttime symptoms associated with LARS syndrome and enhance sleep quality. Therefore, this study aims to investigate the impact of TAI on the symptoms of LARS syndrome.

The 2 groups in the trial

  • Loperamide groupNo study treatment, for comparison

    The group only takes loperamide in the evening (2mg once daily orally)

  • Loperamide + Transanal irrigationTreatment being tested

    The group takes Loperamide daily and undergoes transanal irrigation once or twice a week

    Treatment: Transanal Irrigation (TAI)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Safety and Efficacy of Transanal Irrigation in Patients from Low Anterior Resection Syndrome After Rectal Cancer Surgery : a Multicenter Prospective Randomized Controlled Trial (TraLARS Study)
Plain-language title
Bowel rinsing with water for bowel trouble after rectal cancer surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
28 January 2025